
Ensysce Biosciences, Inc. (ENSC) is scheduled to report 3rd quarter earnings on 11/16/2026. Regarding Q3 estimates, Wall Street analysts expect Ensysce Biosciences, Inc. to post earnings of -$0.15 per share.
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| ENSC | Ensysce Biosciences | 0.41 | -1.51 | -78.67% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.41 | -78.67% |

Ensysce Biosciences, Inc. (ENSC) is scheduled to report 3rd quarter earnings on 11/16/2026. Regarding Q3 estimates, Wall Street analysts expect Ensysce Biosciences, Inc. to post earnings of -$0.15 per share.

UBS initiated coverage of Ensysce Biosciences (ENSC) with a Buy rating and $2 price target The company offers an “early-stage but differentiated” opportunity in chronic pain, the analyst tells investors

Ensysce Biosciences ( ($ENSC) ) has shared an announcement. On October 29, 2026, CEO Lynn Kirkpatrick agreed to relinquish the CEO title and assume COO responsibilities after the December 14,

This filing relates to the offer and sale from time to time by the selling stockholders of up to 433.91M shares of common stock. The company is not selling any

Ensysce Biosciences (ENSC) announced that James Morrison, President of Ensysce Biosciences, participated in the Family Office Summit, Dubai, on October 15, 2026. The visit was a central component of Ensysce’s

Cantor Fitzgerald analyst Olivia Brayer Saunders initiated coverage of Ensysce Biosciences (ENSC) with an Overweight rating and $2 price target Ensysce’s acquisition of Cy Biopharma adds CY200, a botanical psilocybin

Cantor Fitzgerald initiated coverage of Ensysce Biosciences (ENSC) with an Overweight rating and $2 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.

Ensysce Biosciences ( ($ENSC) ) has issued an update. On August 5, 2026, Ensysce Biosciences filed a Certificate of Designation for its Series C Non-Voting Convertible Preferred Stock with Delaware

Ensysce Biosciences (ENSC) announced the submission of the protocol for a Phase 2a clinical study of CY200, the Company’s newest drug candidate from the newly acquired Cy Biopharma. This milestone

Ensysce Biosciences (ENSC) hosted a symposium at PainWeek 2026. The Symposium was attended by more than 320 pain management professionals. Dr. Jeff Gudin provided background on the Ensysce novel program
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Apr 1, 2027TBA | $8.14M | ― | ― | 0.02 | -0.07 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.